Your browser doesn't support javascript.
N-antigenemia detection by a rapid lateral flow test predicts 90-day mortality in COVID-19: A prospective cohort study.
Almansa, Raquel; Eiros, Jose María; de Gonzalo-Calvo, David; Postigo, Tamara; Ortega, Alicia; Lopez-Izquierdo, Raul; Moncusí-Moix, Anna; Gort-Paniello, Clara; Dominguez-Gil, Marta; de la Fuente, Amanda; González-González, Laura; Luis-García, Tania; García-Mateo, Nadia; Tedim, Ana P; Rodríguez-Jara, Fátima; Jorge, Noelia; González, Jessica; Torres, Gerard; Gutiérrez-Pérez, Oliver Norberto; Villegas, Maria José; Campo, Sonia; Ayllon, Eva; Ruiz Albi, Tomás; de Frutos Arribas, Julio; Arroyo Domingo, Ainhoa; Abadia-Otero, Jesica; Gómez Barquero, Julia; Trapiello, Wysali; Garcia Frade, Luis Javier; Inglada, Luis; Del Campo, Felix; Bermejo-Martin, Jesús F; Barbé, Ferran; Torres, Antoni.
  • Almansa R; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Department of Cellular Biology, Hystology and Pharmacology, University of Valladolid, Spain; Centro de Investigación Biomé
  • Eiros JM; Microbiology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • de Gonzalo-Calvo D; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Lleida Spain.
  • Postigo T; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Research Unit, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Ortega A; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Research Unit, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Lopez-Izquierdo R; Emergency Medicine Department, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Moncusí-Moix A; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Lleida Spain.
  • Gort-Paniello C; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Lleida Spain.
  • Dominguez-Gil M; Microbiology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • de la Fuente A; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Research Unit, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • González-González L; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain.
  • Luis-García T; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain.
  • García-Mateo N; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Research Unit, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Tedim AP; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Research Unit, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Rodríguez-Jara F; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Lleida Spain.
  • Jorge N; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain.
  • González J; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Lleida Spain.
  • Torres G; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Lleida Spain.
  • Gutiérrez-Pérez ON; Hematology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Villegas MJ; Hematology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Campo S; Hematology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Ayllon E; Hematology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Ruiz Albi T; Pneumology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • de Frutos Arribas J; Pneumology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain; Department of Medicine, Dermatology and Toxicology, School of Medicine, University of Valladolid, Valladolid, Spain.
  • Arroyo Domingo A; Pneumology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Abadia-Otero J; Internal Medicine Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Gómez Barquero J; Internal Medicine Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Trapiello W; Clinical Analysis Service, Hospital Clínico Universitario de Valladolid, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Garcia Frade LJ; Hematology Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Inglada L; Internal Medicine Service, Hospital Universitario Río Hortega, Gerencia Regional de Salud de Castilla y León, Valladolid, Spain.
  • Del Campo F; Department of Medicine, Dermatology and Toxicology, School of Medicine, University of Valladolid, Valladolid, Spain; Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN), Instituto de Salud Carlos III, Madrid, Spain; Pneumology Service, Hospital Univers
  • Bermejo-Martin JF; Group for Biomedical Research in Sepsis (BioSepsis), Instituto de Investigación Biomédica de Salamanca, (IBSAL), Gerencia Regional de Salud de Castilla y León, Salamanca, Spain; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Re
  • Barbé F; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Translational Research in Respiratory Medicine, University Hospital Arnau de Vilanova and Santa Maria, IRB Lleida, Lleida Spain.
  • Torres A; Centro de Investigación Biomédica en Red en Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Spain; Department of Pulmonology, Hospital Clinic de Barcelona, Universidad de Barcelona, Institut D investigacions August Pi I Sunyer (IDIBAPS), Barcelona, Spain; Catalan Institution for
Clin Microbiol Infect ; 28(10): 1391.e1-1391.e5, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-1866994
ABSTRACT

OBJECTIVES:

To evaluate if the detection of N antigen of SARS-CoV-2 in plasma by a rapid lateral flow test predicts 90-day mortality in COVID-19 patients hospitalized at the wards.

METHODS:

The presence of N-antigenemia was evaluated in the first 36 hours after hospitalization in 600 unvaccinated COVID-19 patients, by using the Panbio COVID-19 Ag Rapid Test Device from Abbott (Abbott Laboratories Inc., Chicago, IL, USA). The impact of N-antigenemia on 90-day mortality was assessed by multivariable Cox regression analysis.

RESULTS:

Prevalence of N-antigenemia at hospitalization was higher in nonsurvivors (69% (82/118) vs. 52% (250/482); p < 0.001). The patients with N-antigenemia showed more frequently RNAemia (45.7% (148/324) vs. 19.8% (51/257); p < 0.001), absence of anti-SARS-CoV-2 N antibodies (80.7% (264/327) vs. 26.6% (69/259); p < 0.001) and absence of S1 antibodies (73.4% (240/327) vs. 23.6% (61/259); p < 0.001). The patients with antigenemia showed more frequently acute respiratory distress syndrome (30.1% (100/332) vs. 18.7% (50/268); p = 0.001) and nosocomial infections (13.6% (45/331) vs. 7.9% (21/267); p = 0.026). N-antigenemia was a risk factor for increased 90-day mortality in the multivariable analysis (HR, 1.99 (95% CI,1.09-3.61), whereas the presence of anti-SARS-CoV-2 N-antibodies represented a protective factor (HR, 0.47 (95% CI, 0.26-0.85).

DISCUSSION:

The presence of N-antigenemia or the absence of anti-SARS-CoV-2 N-antibodies after hospitalization is associated to increased 90-day mortality in unvaccinated COVID-19 patients. Detection of N-antigenemia by using lateral flow tests is a quick, widely available tool that could contribute to early identify those COVID-19 patients at risk of deterioration.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Etiology study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Type of study: Cohort study / Diagnostic study / Etiology study / Experimental Studies / Observational study / Prognostic study Limits: Humans Language: English Journal: Clin Microbiol Infect Journal subject: Communicable Diseases / Microbiology Year: 2022 Document Type: Article